We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Grants BMS Priority Review for Daklinza sNDAs
The FDA has granted priority review status for three sNDAs for Bristol-Myers Squibb’s Daklinza, potentially expanding the firm’s footprint in the roughly $13 billion U.S. hepatitis C market.